Background: Sickle cell disease is the most common genetic disorder in the world. It is a real public health problem in sub-Saharan Africa. Early screening makes it possible to diagnose the disease in the first few days of life and to start early treatment to prevent serious complications. The aim of this study was to determine the prevalence of sickle cell disease in Mbujimayi among children under the age of 5 during routine vaccination. Method: Prospective study conducted over a period of 6 months, from 05 December 2023 to 05 June 2024, in Mbujimayi. The main intervention of the study was systematic screening for sickle cell disease in children under 5 years of age during routine vaccination. The HemoTypeSC immuno-chromatographic test was used, and SS homozygous cases were confirmed by hemoglobin electrophoresis. Results: The prevalence of sickle cell disease was 6% (66/1100). The HemoTypeSC test demonstrated a sensitivity of 99% and a specificity of 100%. Significant correlations were observed, showing a higher prevalence in boys (p < 0.003), as well as an association with a history of transfusion (p < 0.01), hospitalization (p < 0.01), unexplained pain (p < 0.01) and the presence of sickle cell disease in the siblings (p < 0.01). Acceptability of the test was 100%. Conclusion: This study highlights the importance of early screening for sickle cell disease in children under 5 years of age in Mbujimayi. A proactive, targeted approach not only makes it possible to detect the disease at an early stage, but also to direct efforts towards appropriate management and better prevention of the complications associated with sickle cell disease. The HemoTypeSC immunochromatographic test is proving to be a valuable tool for screening for sickle cell disease in primary care.
References
[1]
Thiam, L., Dramé, A., Coly, I.Z., Diouf, F.N., Seck, N., Boiro, D., et al. (2017) Profils épidemiologiques, cliniques et hématologiques de la drépanocytose homozygote SS en phase inter critique chez l’enfant à Ziguinchor, Sénégal. Pan African Medical Journal, 28, Article 208. https://doi.org/10.11604/pamj.2017.28.208.14006
[2]
Comité régional de l’Afrique (2011) Drépanocytose: Une stratégie pour la Région africaine de l’OMS: Rapport du Directeur régional.
[3]
Piel, F.B., Steinberg, M.H. and Rees, D.C. (2017) Sickle Cell Disease. New England Journal of Medicine, 376, 1561-1573. https://doi.org/10.1056/nejmra1510865
[4]
Piel, F.B., Hay, S.I., Gupta, S., Weatherall, D.J. and Williams, T.N. (2013) Global Burden of Sickle Cell Anaemia in Children under Five, 2010-2050: Modelling Based on Demographics, Excess Mortality, and Interventions. PLOS Medicine, 10, e1001484. https://doi.org/10.1371/journal.pmed.1001484
Kjellander, C., Sennström, M.K.B., Stiller, V. and Ågren, A. (2015) [Sickle Cell Anemia Causes Varied Symptoms and High Morbidity. Serious Prognosis in the Most Common Genetic Disease in the World]. Lakartidningen, 112.
[7]
Shongo, M.Y.P., Mukuku, O., Lubala, T.K., Mutombo, A.M., Kanteng, G.W., Umumbu, W.S., et al. (2014) [Sickle Cell Disease in Stationary Phase in 6-59 Months Children in Lubumbashi: Epidemiology and Clinical Features]. Pan African Medical Journal, 19, Article 71.
[8]
Mukinayi, B.M., Cibeyibeyi, G.K., Tumba, G.D. and Gulbis, B. (2021) Drépanocytose en République Démocratique du Congo: Quels sont les obstacles à un traitement par hydroxyurée? PanAfricanMedicalJournal, 38, Article 41. https://doi.org/10.11604/pamj.2021.38.41.18718
[9]
Mbiya, B.M., Kalombo, D.K., Mukendi, Y.N., Daubie, V., Mpoyi, J.K., Biboyi, P.M., et al. (2021) Improvement of SCD Morbimortality in Children: Experience in a Remote Area of an African Country. BMCHealthServicesResearch, 21, Article No. 294. https://doi.org/10.1186/s12913-021-06286-7
[10]
Steele, C., Sinski, A., Asibey, J., Hardy‐Dessources, M., Elana, G., Brennan, C., et al. (2019) Point-Of-Care Screening for Sickle Cell Disease in Low-Resource Settings: A Multi-Center Evaluation of Hemotypesc, a Novel Rapid Test. AmericanJournalofHematology, 94, 39-45. https://doi.org/10.1002/ajh.25305
[11]
Housni, H.E., Vandesompele, J., Vannuffel, P., Gulbis, B., Parma, J. and Cochaux, P. (2007) Rapid and Easy Prenatal Diagnosis of Sickle Cell Anemia Using Double-Dye LNA Probe Technology. British Journal of Haematology, 136, 509-610. https://pubmed.ncbi.nlm.nih.gov/17233849/
[12]
Aimé, A.K., Etienne, S.M., Mbongi, D., Nsonso, D., Serrao, E., Malaika Léon, T.M., et al. (2022) Dépistage hospitalier de la drépanocytose en République Démocratique du Congo (RDC) par HemoTypeSC: Cas de la ville de Kindu. PanAfricanMedicalJournal, 41, Article 134. https://doi.org/10.11604/pamj.2022.41.134.30187
[13]
Adegoke, S.A., Oladimeji, O.I., Akinlosotu, M.A., Akinwumi, A.I. and Matthew, K.A. (2022) Hemotypesc Point-Of-Care Testing Shows High Sensitivity with Alkaline Cellulose Acetate Hemoglobin Electrophoresis for Screening Hemoglobin SS and SC Genotypes. Hematology, TransfusionandCellTherapy, 44, 341-345. https://doi.org/10.1016/j.htct.2020.11.010
[14]
Segbena, A.Y., Guindo, A., Buono, R., Kueviakoe, I., Diallo, D.A., Guernec, G., et al. (2018) Diagnostic Accuracy in Field Conditions of the Sickle SCAN® Rapid Test for Sickle Cell Disease among Children and Adults in Two West African Settings: The DREPATEST Study. BMCHematology, 18, Article No. 26. https://doi.org/10.1186/s12878-018-0120-5
[15]
(2026) Perspectives de la population mondiale. https://worldpopulationreview.com/cities/dr-congo/mbuji-mayi
[16]
Nguyen-Khoa, T., Mine, L., Allaf, B., Ribeil, J., Remus, C., Stanislas, A., et al. (2018) Sickle SCAN™ (Biomedomics) Fulfills Analytical Conditions for Neonatal Screening of Sickle Cell Disease. Annalesdebiologieclinique, 76, 416-420. https://doi.org/10.1684/abc.2018.1354
[17]
Badawi, M., Garoot, S., Tahlawi, M., Hindawi, S. and Adam, S. (2020) Evaluation of a Point-Of-Care Method for Screening Blood Donors for Sickle Cell Status. Transfusion, 60, S10-S14. https://doi.org/10.1111/trf.15586
[18]
Katawandja, A.L., Nzengu-Lukusa, F., Nzongola-Nkasu, D.K. and Muepu, L.T. (2021) Neonatal Screening for Sickel Cell Disease in Urban Areas with Limited Resources: Case of Kindu City, East of the Democratic Republic of Congo. Open Access Library Journal, 8, 1-10. https://doi.org/10.4236/oalib.1107097
[19]
Kasai, E.T., Gulbis, B., Ntukamunda, J.K., Bours, V., Batina Agasa, S., Marini Djang’eing’a, R., et al. (2023) Newborn Screening for Sickle Cell Disease in Kisangani, Democratic Republic of the Congo: An Update. Hematology, 28, Article ID: 2213043. https://doi.org/10.1080/16078454.2023.2213043
[20]
Katamea, T., Mukuku, O., Mpoy, C.W., Mutombo, A.K., Luboya, O.N. and Wembonyama, S.O. (2024) Newborn Screening for Sickle Cell Disease in Lubumbashi, Democratic Republic of the Congo: An Update on the Prevalence of the Disease. JournalofHematologyandAlliedSciences, 3, 120-124. https://doi.org/10.25259/jhas_11_2023
[21]
Tshilolo, L., Aissi, L.M., Lukusa, D., Kinsiama, C., Wembonyama, S., Gulbis, B., et al. (2009) Neonatal Screening for Sickle Cell Anaemia in the Democratic Republic of the Congo: Experience from a Pioneer Project on 31 204 Newborns. JournalofClinicalPathology, 62, 35-38. https://doi.org/10.1136/jcp.2008.058958
[22]
Peace, I.A., Ajaegbu, O., Angela, B.N., Helen, O.O., Lynda, N.C., Benedeth, O.N., et al. (2024) Haemoglobin Phenotype of Newborn at Asaba Specialist Hospital, Delta State Nigeria: The Need for Newborn Screening. InternationalJournalofInnovativeResearchinMedicalScience, 9, 495-498. https://doi.org/10.23958/ijirms/vol09-i09/1957
Adegoke, S.A., Makalo, L., Sallah, A., Saine, H., Joof, S., Conteh, A., et al. (2024) Point-Of-Care Newborn Screening for Sickle Cell Disease at Selected Health Facilities in the Gambia. Hemoglobin, 48, 169-174. https://doi.org/10.1080/03630269.2024.2369523
[25]
Guindo, A., Cisse, Z., Keita, I., Desmonde, S., Sarro, Y.d.S., Touré, B.A., et al. (2024) Potential for a Large-Scale Newborn Screening Strategy for Sickle Cell Disease in Mali: A Comparative Diagnostic Performance Study of Two Rapid Diagnostic Tests (Sicklescan® and Hemotypesc®) on Cord Blood. BritishJournalofHaematology, 204, 337-345. https://doi.org/10.1111/bjh.19108
[26]
Okeke, C.O., Chianumba, R.I., Isa, H., Asala, S. and Nnodu, O.E. (2022) Using Dried Blood Spot on Hemotypesc™, a New Frontier for Newborn Screening for Sickle Cell Disease in Nigeria. FrontiersinGenetics, 13, Article 1013858. https://doi.org/10.3389/fgene.2022.1013858
[27]
Mendes, I., Costa, A., Lage, J., Monteiro, B., Ferreira, T. and Loureiro, H. (2023) Sickle Cell Disease: Clinical and Sociodemographic Characteristics of Children under Five Years in a Portuguese Hospital. NascereCrescer, 32, 23-30.
[28]
Oron, A.P., Chao, D.L., Ezeanolue, E.E., Ezenwa, L.N., Piel, F.B., Ojogun, O.T., et al. (2020) Caring for Africa’s Sickle Cell Children: Will We Rise to the Challenge? BMCMedicine, 18, Article No. 92. https://doi.org/10.1186/s12916-020-01557-2
[29]
Ebola, H.S.E., Bompemo, P.N., Bwana, T.K., Ntoto, B.N. and Eloko, E.M.G. (2024) Épidémiologie, pré-sentation clinique et traitement de la drépanocytose: Une étude rétrospective à l’hôpital général de référence de Wangata, Mbandaka, République démocratique du Congo. Orapuh Journal, 5, e1164. https://www.orapuh.org/ojs/index.php/orapj/article/view/e1164
[30]
Aloni, M.N., Tshimanga, B.K., Ekulu, P.M., Ehungu, J.L.G. and Ngiyulu, R.M. (2013) Malaria, Clinical Features and Acute Crisis in Children Suffering from Sickle Cell Disease in Resource-Limited Settings: A Retrospective Description of 90 Cases. PathogensandGlobalHealth, 107, 198-201. https://doi.org/10.1179/2047773213y.0000000089
[31]
Qua, K., Swiatkowski, S.M., Gurkan, U.A. and Pelfrey, C.M. (2021) A Retrospective Case Study of Successful Translational Research: Gazelle Hb Variant Point-Of-Care Diagnostic Device for Sickle Cell Disease. JournalofClinicalandTranslationalScience, 5, e207. https://doi.org/10.1017/cts.2021.871
